Phase III Clascoterone Data Shows Sustained Hair Growth; Scalp SD Metabolomics Reveals Key Inflammatory Markers
Cosmo Pharmaceuticals reported positive 12-month Phase III data for Clascoterone 5% topical solution in male androgenetic alopecia, showing sustained hair growth and a safety profile comparable to vehicle. A separate metabolomics study characterized key inflammatory markers in scalp seborrheic dermatitis, identifying Malassezia fungi and specific free fatty acids as central drivers of the condition.